Nanopublications LDF server

Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RA4EAS9qGkyp6LpE6fon0GU2Go9hmxEHvkHUUvWmypews#assertion>. }

• association type Statement assertion.
• association label "rapamune is an mtor inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged 13 years receiving renal transplants 1 1 1 1 1 1 1 2 14 3 rapamune is an mtor inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis 1 3 rapamune sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants in patients at low to moderate immunologic risk see dosage and administration 2 2 in patients at high immunologic risk see dosage and administration 2 3 clinical studies 14 3 cyclosporine withdrawal has not been studied in patients with banff grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal those who are dialysis dependent those with serum creatinine 4 5 mg dl black patients patients of multi organ transplants secondary transplants or those with high levels of panel reactive antibodies see clinical studies 14 2 in patients at high immunologic risk see clinical studies 14 3 in pediatric patients see adverse reactions 6 5 clinical studies 14 6 the safety and efficacy of de novo see warnings and precautions 5 12 the safety and efficacy of conversion from calcineurin inhibitors to rapamune see clinical studies 14 4 rapamune sirolimus is indicated for the treatment of patients with lymphangioleiomyomatosis lam" assertion.
• association object DOID_3319 assertion.
• association predicate treats assertion.
• association subject drugbank:DB00877 assertion.
• association relation TreatmentIndication assertion.
• drugbank:DB00877 category Drug assertion.
• DOID_3319 category Disease assertion.
• association provided_by NeuroDKG assertion.
• association association_type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.